Ird Luxturna denied as not medically necessary by Cigna?

Cigna's specific coverage criteria for ird luxturna are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies Luxturna for IRD on Medical-Necessity Grounds

Cigna's medical-necessity denials for Luxturna (voretigene neparvovec) in RPE65-associated inherited retinal dystrophy typically reflect one of three gaps in the submitted record: (1) absence of documented molecular genetic confirmation of biallelic RPE65 pathogenic variants; (2) insufficient documentation of retained viable retinal cells (a key clinical criterion in the prescribing label); or (3) inadequate characterization of the current stage and severity of vision loss. Luxturna is expensive and clinically specific — Cigna's review process requires highly precise documentation.

## Your Federal Appeal Rights

• ERISA §503: You are entitled to a full-and-fair internal review, including a peer-to-peer review between your retinal specialist and Cigna's medical reviewer. Request the peer-to-peer explicitly — it is often the most efficient path to reversal for complex gene therapy cases.
• ACA §2719 external review: Available after exhausting internal appeals, generally within four months of the denial notice. Given that RPE65-associated retinal dystrophy causes irreversible and progressive vision loss, apply for expedited external review — the irreversibility of the harm qualifies this as urgent in most external review frameworks.
• State insurance department: File a complaint in parallel to create a regulatory record, particularly if the denial lacks specific clinical basis.

## Concrete Appeal Steps

1. Obtain the denial letter and identify each specific medical-necessity criterion Cigna states was not met. 2. Request Cigna's coverage policy for Luxturna in writing. 3. Review the FDA prescribing label for Luxturna carefully — confirm your documentation addresses each eligibility criterion stated there. 4. Request a peer-to-peer review between your retinal specialist and Cigna's reviewer. 5. Compile and submit the documentation package below, mapped to each denial criterion. 6. If denied internally, file for expedited external review immediately.

## Documentation to Gather

• Genetic test results: A formal molecular genetics report confirming biallelic pathogenic variants in the RPE65 gene — this is non-negotiable for demonstrating eligibility.
• Retinal viability assessment: Ophthalmology records documenting viable retinal cells — your retinal specialist should address this specifically in their notes and letter, as it is a key criterion in the FDA label.
• Visual function testing: Electroretinography (ERG) results, visual field test results, full-field stimulus testing (FST), and best-corrected visual acuity measurements — provide a longitudinal record showing the progression of vision loss.
• Retinal imaging: OCR (optical coherence tomography) and/or fundus photography documenting the structural status of the retina.
• Retinal specialist or ophthalmologist medical-necessity letter: Should address each criterion in Cigna's coverage policy and the FDA label directly, using the language of those documents.
• Center of excellence or treating facility credentials: Luxturna must be administered at a qualified treatment center — documenting this may be required.

## Criteria-Mapping Structure

| Cigna/FDA Label Criterion | Supporting Chart Documentation | |---|---| | Biallelic RPE65 pathogenic variants confirmed | Genetic test report [date, lab, specific variants identified] | | Sufficient viable retinal cells | Retinal specialist note; imaging report [date] | | [Each additional criterion from Cigna policy] | [Exact test result, note, or date] |